EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Advances in Atopic Dermatitis Management: The Role of Lebrikizumab

Saba Mushtaq, Hafsa Shuja, Hamza Yousuf Ibrahim, Syeda Farwa Zehra, Umer Wamiq, Muhammad Faisal, Fawaz Ur Rehman, Ayesha Abdullah, Ehsanullah Alokozay

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/1682557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 14.05.2026. Verfasst von Saba Mushtaq und 8 weiteren Autor:innen. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by intense pruritus and eczematous lesions, significantly impacting patients’ quality of life. Current treatment options include topical therapies (e.g., corticosteroids, calcineurin inhibitors, and topical Janus kinase [JAK] inhibitors), phototherapy, and systemic agents such as oral corticosteroids and JAK inhibitors. Advances in the understanding of AD immunopathogenesis have facilitated the development of targeted biologic therapies. Lebrikizumab, a humanized monoclonal antibody that selectively inhibits interleukin‐13 (IL‐13) signaling, has emerged as a potential therapeutic option for moderate‐to‐severe disease. This narrative review summarizes the evolving landscape of AD management, focusing on the mechanism of action, clinical efficacy, and safety profile of lebrikizumab, with evidence derived from Phase II and III clinical trials. It has been associated with improvements in skin clearance, reduction in pruritus, and enhanced quality of life. Its safety profile appears generally acceptable, with most reported adverse events being mild to moderate. Overall, it may serve as a valuable addition to current therapeutic options for atopic dermatitis, although further long‐term and comparative studies are needed to better establish its role in clinical practice.

Zitieren

APA

Mushtaq, S., Shuja, H., Ibrahim, H. Y., Zehra, S. F., Wamiq, U., Faisal, M., Rehman, F. U., Abdullah, A., & Alokozay, E. (2026). Advances in Atopic Dermatitis Management: The Role of Lebrikizumab. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1682557

Vancouver

Mushtaq S, Shuja H, Ibrahim HY, Zehra SF, Wamiq U, Faisal M, et al. Advances in Atopic Dermatitis Management: The Role of Lebrikizumab. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1682557

BibTeX
@article{Mushtaq2026,
  author = {Mushtaq, Saba and Shuja, Hafsa and Ibrahim, Hamza Yousuf and Zehra, Syeda Farwa and Wamiq, Umer and Faisal, Muhammad and Rehman, Fawaz Ur and Abdullah, Ayesha and Alokozay, Ehsanullah},
  title = {Advances in Atopic Dermatitis Management: The Role of Lebrikizumab},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/1682557}
}
Kostenlos starten →